Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMAG PHARMACEUTICALS, INC.AMAG · Entity 145305 | COO & CFO | March 10, 2020 | March 12, 2020 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | COO & CFO | March 10, 2025 | March 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMAG PHARMACEUTICALS, INC.
Report date March 10, 2020 · Filed March 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,659 |
Reported balance
After 2020-03-10 transaction · row 1
1 source rowRow 1 · 2020-03-10 · Grant · Acquired 30,000 · Balance 98,659 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in three equal annual installments with the first installment vesting on March 10, 2021. F3: Not applicable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2030-03-10 | Direct | 45,000 |
Reported balance
After 2020-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-10 · Grant · Acquired 45,000 · Balance 45,000 F3: Not applicable. F4: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").
F2: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in three equal annual installments with the first installment vesting on March 10, 2021.
F3: Not applicable.
F4: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.
Scholar Rock Holding Corp
Report date March 10, 2025 · Filed March 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,430 |
Reported balance
After 2025-03-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-10 · Exercise / conversion · Acquired 21,690 · Balance 162,430 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F2: Consists of 51,085 shares of common stock and 111,345 restricted stock units ("RSUs"). |
| Common StockSEC Table I · non-derivative | Direct | 205,552 |
Reported balance
After 2025-03-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-03-10 · Exercise / conversion · Acquired 43,122 · Balance 205,552 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F3: Consists of 94,207 shares of common stock and 111,345 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 230,467 |
Reported balance
After 2025-03-10 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-03-10 · Exercise / conversion · Acquired 24,915 · Balance 230,467 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F4: Consists of 119,122 shares of common stock and 111,345 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 235,780 |
Reported balance
After 2025-03-10 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2025-03-10 · Exercise / conversion · Acquired 5,313 · Balance 235,780 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F5: Consists of 124,435 shares of common stock and 111,345 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 253,637 |
Reported balance
After 2025-03-10 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2025-03-10 · Exercise / conversion · Acquired 17,857 · Balance 253,637 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F6: Consists of 142,292 shares of common stock and 111,345 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 140,740 |
Reported balance
After 2025-03-10 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2025-03-10 · Sale · Disposed 112,897 · Balance 140,740 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.03 to $35.765, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F8: Consists of 29,395 shares of common stock and 111,345 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 111,345 |
Reported balance
After 2025-03-10 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2025-03-10 · Sale · Disposed 29,395 · Balance 111,345 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.53 to $35.025, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F10: Consists of 111,345 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2030-07-16 | Direct | 0 |
Reported balance
After 2025-03-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-03-10 · Exercise / conversion · Disposed 21,690 · Balance 0 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F11: 100% of the shares underlying the option are fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.08 · Expires 2032-02-14 | Direct | 14,378 |
Reported balance
After 2025-03-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-03-10 · Exercise / conversion · Disposed 43,122 · Balance 14,378 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F12: Options vest and become exercisable in sixteen quarterly installments over four years. Vesting commenced on January 1, 2022 and the first vesting event shall occur three months thereafter; provided the reporting person continues to have a service relationship with the Company on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.86 · Expires 2032-06-16 | Direct | 12,462 |
Reported balance
After 2025-03-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-03-10 · Exercise / conversion · Disposed 24,915 · Balance 12,462 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F13: Options vest and become exercisable in twelve quarterly installments over three years, with the first quarterly installment to vest on September 16, 2022 and each additional installment to vest quarterly thereafter, provided the individual continues to have a service relationship with the Company on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2033-02-13 | Direct | 42,500 |
Reported balance
After 2025-03-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-03-10 · Exercise / conversion · Disposed 5,313 · Balance 42,500 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F14: The shares underlying this option vest in sixteen quarterly installments over four years, with the first quarterly installment vested on April 1, 2023 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.75 · Expires 2034-02-12 | Direct | 53,573 |
Reported balance
After 2025-03-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-03-10 · Exercise / conversion · Disposed 17,857 · Balance 53,573 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024. F15: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2024 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2024.
F2: Consists of 51,085 shares of common stock and 111,345 restricted stock units ("RSUs").
F3: Consists of 94,207 shares of common stock and 111,345 RSUs.
F4: Consists of 119,122 shares of common stock and 111,345 RSUs.
F5: Consists of 124,435 shares of common stock and 111,345 RSUs.
F6: Consists of 142,292 shares of common stock and 111,345 RSUs.
F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.03 to $35.765, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8: Consists of 29,395 shares of common stock and 111,345 RSUs.
F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.53 to $35.025, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F10: Consists of 111,345 RSUs.
F11: 100% of the shares underlying the option are fully vested.
F12: Options vest and become exercisable in sixteen quarterly installments over four years. Vesting commenced on January 1, 2022 and the first vesting event shall occur three months thereafter; provided the reporting person continues to have a service relationship with the Company on such vesting date.
F13: Options vest and become exercisable in twelve quarterly installments over three years, with the first quarterly installment to vest on September 16, 2022 and each additional installment to vest quarterly thereafter, provided the individual continues to have a service relationship with the Company on such vesting date.
F14: The shares underlying this option vest in sixteen quarterly installments over four years, with the first quarterly installment vested on April 1, 2023 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on each such vesting date.
F15: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2024 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2021 Filed Nov 16, 2021 02:28 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 49,848 | $35.12 | $1,750,437.44 |
DisclosureSEC source: 0001104659-21-139527 · tm2133015-1_4seq1.xml · nonDerivative · entry 4 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,150 F1 · shares: This transaction was effected pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 24,150 RSUs. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 02:28 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | OtherCommon Stock | 49,848 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-139527 · tm2133015-1_4seq1.xml · nonDerivative · entry 3 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,998 F1 · shares: This transaction was effected pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F5 · price: The shares of common stock were acquired at a price per share of $13.83, $20.52 and $21.21 as reported in Table II. F6 · balance_after: Consists of 49,848 shares of common stock and 24,150 RSUs. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU award will vest annually over four years, subject to a continued service relationship with the Issuer on such vesting date. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 02:28 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,773 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001104659-21-139527 · tm2133015-1_4seq1.xml · derivative · entry 9 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,227 Underlying: Common Stock · 7,773 shares Expires 2030-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Shares vest over four years, with 25% vesting on July 16, 2021, and the remainder of shares vesting in twelve (12) quarterly installments thereafter, subject to such individual's continued service relationship with the Issuer through each such date. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 02:28 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,079 | $0.00 Strike: $21.21 | $0.00 |
DisclosureSEC source: 0001104659-21-139527 · tm2133015-1_4seq1.xml · derivative · entry 8 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,079 shares Expires 2029-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 02:28 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,722 | $0.00 Strike: $20.52 | $0.00 |
DisclosureSEC source: 0001104659-21-139527 · tm2133015-1_4seq1.xml · derivative · entry 7 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,722 shares Expires 2028-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 02:28 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 23,574 | $35.20 | $829,856.66 |
DisclosureSEC source: 0001104659-21-139527 · tm2133015-1_4seq1.xml · nonDerivative · entry 2 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,150 F1 · shares: This transaction was effected pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 24,150 RSUs. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 02:28 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | OtherCommon Stock | 23,574 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-139527 · tm2133015-1_4seq1.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,724 F1 · shares: This transaction was effected pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F5 · price: The shares of common stock were acquired at a price per share of $13.83, $20.52 and $21.21 as reported in Table II. F2 · balance_after: Consists of 23,574 shares of common stock and 24,150 restricted stock units ("RSU"). Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU award will vest annually over four years, subject to a continued service relationship with the Issuer on such vesting date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:10 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 80,500 | $0.00 Strike: $58.93 | $0.00 |
DisclosureSEC source: 0001179110-21-001251 · edgar.xml · derivative · entry 2 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,301 Underlying: Common Stock · 80,500 shares Expires 2031-02-01 F2 · derivative.exercise_date: Shares will vest and become exercisable quarterly over four years, subject to a continued service relationship with the Issuer on such vesting date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:10 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 24,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001251 · edgar.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,150 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU award will vest and become exercisable quarterly over four years, subject to a continued service relationship with the Issuer on such vesting date. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:31 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001179110-20-008342 · edgar.xml · derivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-07-16 F1 · derivative.exercise_date: Shares will vest over four years, with 25% vesting on July 16, 2021 and the remainder vesting in 12 quarterly installments thereafter, subject to such individual's continued service through each such date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:25 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $17.65 | $0.00 |
DisclosureSEC source: 0001179110-20-007539 · edgar.xml · derivative · entry 1 Myles Edward H · CIK 0001358219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 16:12 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 45,000 | Not disclosed Strike: $7.27 | Not disclosed |
DisclosureSEC source: 0001104659-20-032487 · a4.xml · derivative · entry 2 Myles Edward H · CIK 0001358219 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-03-10 F3 · price: Not applicable. F4 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 16:12 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-032487 · a4.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,659 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in three equal annual installments with the first installment vesting on March 10, 2021. F3 · price: Not applicable. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:49 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,021 | $7.75 | $7,912.75 |
DisclosureSEC source: 0001104659-20-029290 · a4.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,659 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,333 restricted stock units ("RSUs") on March 2, 2020. F2 · balance_after: Reporting person's total beneficial ownership has been adjusted to reflect that no shares were awarded pursuant to the performance-based RSU award granted on February 23, 2017. The reporting person had previously reported beneficial ownership of 7,500 shares pursuant to the RSU award, which represented the target number of shares that could have been delivered based on the achievement of certain relative total stockholder return targets over a three year performance period, which were not met, and which target share amount was previously reported on a Form 4 filed on February 27, 2017. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 16:49 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,386 | $8.84 | $12,252.24 |
DisclosureSEC source: 0000792977-20-000020 · wf-form4_158266733165519.xml · nonDerivative · entry 2 Myles Edward H · CIK 0001358219 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,180 F2 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,999 restricted stock units on February 25, 2020. Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 16:49 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 867 | $9.50 | $8,236.50 |
DisclosureSEC source: 0000792977-20-000020 · wf-form4_158266733165519.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,566 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,501 restricted stock units on February 23, 2020. Read SEC document |
| May 21, 2019 Filed May 24, 2019 01:43 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 5,079 | $0.00 Strike: $21.21 | $0.00 |
DisclosureSEC source: 0001104659-19-031599 · a4.xml · derivative · entry 1 Myles Edward H · CIK 0001358219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,079 Underlying: Common Stock · 5,079 shares Expires 2029-05-21 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:22 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,964 | $12.47 | $24,491.08 |
DisclosureSEC source: 0000792977-19-000074 · wf-form4_155510055703306.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,433 F1 · shares: Represents shares automatically withheld to satisfy the reporting person's tax obligations in connection with the vesting of 6,668 restricted stock units on April 11,2019. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:01 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,064 | $14.76 | $15,704.64 |
DisclosureSEC source: 0000792977-19-000043 · wf-form4_155182685808707.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,397 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,333 restricted stock units on March 2, 2019. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:27 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $15.51 | Not disclosed |
DisclosureSEC source: 0000792977-19-000029 · wf-form4_155131002377206.xml · derivative · entry 3 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-25 F3 · price: Not applicable. F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:27 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000029 · wf-form4_155131002377206.xml · nonDerivative · entry 2 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,461 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending February 25, 2022 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:27 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000029 · wf-form4_155131002377206.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,461 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in three equal annual installments with the first installment vesting on February 25, 2020. F3 · price: Not applicable. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 17:45 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 869 | $15.51 | $13,478.19 |
DisclosureSEC source: 0000792977-19-000022 · wf-form4_155122112799049.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,461 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,500 restricted stock units on February 23, 2019. Read SEC document |
| November 19, 2018 Filed Nov 22, 2018 01:02 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (right to buy) · Derivative | 20,316 | $0.00 Strike: $20.52 | $0.00 |
DisclosureSEC source: 0001104659-18-069648 · a4.xml · derivative · entry 1 Myles Edward H · CIK 0001358219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,316 Underlying: Common Stock · 20,316 shares Expires 2028-11-19 F1 · derivative.exercise_date: This option vests monthly over three (3) years, with the first monthly amount vesting on December 19, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:04 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,964 | $19.85 | $38,985.40 |
DisclosureSEC source: 0000792977-18-000048 · wf-form4_153064825208245.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,330 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 6,666 restricted stock units ("RSUs") on April 11, 2018. Due to the black-out policies implemented by AMAG Pharmaceuticals, Inc. (the "Issuer"), the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until July 2, 2018, at which time 1,964 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:20 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 24,000 | Not disclosed Strike: $21.00 | Not disclosed |
DisclosureSEC source: 0001179110-18-003692 · edgar.xml · derivative · entry 4 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2028-03-02 F3 · price: Not applicable. F7 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:20 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 854 | $21.00 | $17,934.00 |
DisclosureSEC source: 0001179110-18-003692 · edgar.xml · nonDerivative · entry 3 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,294 F6 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,499 RSUs on February 23, 2018. Due to the black-out policies implemented by the Issuer, the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until March 2, 2018, at which time an aggregate of 854 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:20 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-003692 · edgar.xml · nonDerivative · entry 2 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,148 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F5 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending March 1, 2021 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:20 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-003692 · edgar.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,148 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on March 2, 2019. F3 · price: Not applicable. F4 · balance_after: Reporting Person's total beneficial ownership reflects the purchase of 1,325 shares through an Employee Stock Purchase Plan on November 30, 2017. Read SEC document |
| May 08, 2017 Filed May 10, 2017 16:49 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 2,177 | $18.55 | $40,383.35 |
DisclosureSEC source: 0001179110-17-006987 · edgar.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,823 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 6,666 restricted stock units ("RSUs") on April 11, 2017. Due to the black-out policies implemented by AMAG Pharmaceuticals, Inc. (the "Issuer"), the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until May 8, 2017, at which time 2,177 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 18:56 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $23.75 | Not disclosed |
DisclosureSEC source: 0001179110-17-003319 · edgar.xml · derivative · entry 3 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-02-23 F3 · price: Not applicable. F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 18:56 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-003319 · edgar.xml · nonDerivative · entry 2 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending December 31, 2019, subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 18:56 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-003319 · edgar.xml · nonDerivative · entry 1 Myles Edward H · CIK 0001358219 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on February 23, 2018. F3 · price: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.